Skip to main content
Equibles

JANE STREET GROUP, LLC

Position in NVCT — Nuvectis Pharma, Inc.

CIK 1595888 NEW YORK, NY
Back to NVCT Full portfolio

Position in NVCT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$286,552
+$286,552 QoQ
Shares Held
15,582
Ownership
0.048%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#41
of 82 holders
Holding Since
Mar 2023
7 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in NVCT Over Time

Shares Held

Position Value (USD)

Derivatives in NVCT

reported options exposure · as of Jun 30, 2026
CallValue
$1,513,497
CallShares
82,300
PutValue
$485,496
PutShares
26,400

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

JANE STREET GROUP, LLC holds $1,372,940,661 across 293 Biotechnology names. NVCT ranks #154 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 BBIO
BridgeBio Pharma, Inc.
 2,934,193 $218,538,693
2 MDGL
Madrigal Pharmaceuticals, Inc.
 191,541 $102,847,939
3 AXSM
Axsome Therapeutics, Inc.
 403,995 $98,885,855
4 TGTX
Tg Therapeutics, Inc.
 1,752,646 $96,290,370
5 EXEL
Exelixis, Inc.
 1,402,438 $76,306,651
6 QURE
uniQure N.V.
 1,610,483 $74,178,846
7 HALO
Halozyme Therapeutics, Inc.
 694,684 $54,372,915
8 TVTX
Travere Therapeutics, Inc.
 938,699 $53,327,489

All Filings in NVCT

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $286,552 15,582
2026-06-30 $1,513,497 82,300
2026-06-30 $485,496 26,400
2026-03-31 $142,232 18,400
2025-12-31 $135,145 17,900
2025-09-30 $158,193 26,278
2025-03-31 $413,260 42,299
2024-06-30 $107,742 17,021
2023-03-31 $145,337 11,086